Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...

Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...

Swapping out longer learning modules for “bite-sized” games has improved associate performance, the grocer shared at the ...

BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...

There’s a lot of debate about weight machines in the fitness world. Some people gravitate towards them because they seem a ...

While it's not ready to join the workforce yet, Atlas, an AI-powered humanoid, is learning how to do human tasks.

The U.S. Navy demonstrated the manned-unmanned teaming capabilities of BQM-177s using Shield AI’s Hivemind software in a simulated CCA air combat ...

With all the buzzwords surrounding artificial intelligence, from smiling promotions to angry chagrins—promises that it will revolutionize how we work and play, while “slop” becomes Merriam-Webster’s ...

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...